Drug intelligence / Profile preview

[18F]F-RESCA-R8B4-RenJi Hospital

Development stage
Phase 2
Lead developer
Renji Hospital
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

[18F]F-RESCA-R8B4-RenJi Hospital is a CD70-targeted immuno-positron emission tomography (immunoPET) imaging tracer developed by RenJi Hospital of Shanghai Jiao Tong University School of Medicine. The agent consists of the R8B4 single-domain antibody (sdAb), also known as a nanobody, which specifically binds to the tumor-associated antigen CD70. It is radiolabeled with the positron-emitting isotope fluorine-18 using the aluminum fluoride restrained complexing agent (AlF-RESCA) method, which provides a stable and efficient labeling process. CD70 is a member of the tumor necrosis factor (TNF) superfamily and is highly expressed in several malignancies, including clear cell renal cell carcinoma (ccRCC), nasopharyngeal carcinoma, and various lymphomas, while maintaining low expression in healthy tissues. [18F]F-RESCA-R8B4 is designed to provide high-resolution PET/CT imaging for the non-invasive assessment of CD70 expression, aiding in tumor detection, staging, and the selection of patients for CD70-targeted therapies.

Other names
[18F]R8B418F-labeled CD70-targeted nanobody18F-AlF-RESCA-R8B4
02

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on [18F]F-RESCA-R8B4-RenJi Hospital.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]F-RESCA-R8B4-RenJi Hospital.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call